At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8,145 enrolled
Drug / intervention
Jardiancedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE® Tablets in Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating Jardiance for Diabetes Mellitus, Type 2. Completed, enrolled 8,145 participants across 1 site.
Detailed Summary
Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionNov 2020
Study CompletionDec 2020
TodayJul 2026
First PostedJul 3, 2015
Enrollment StartJun 12, 2015
Primary CompletionNov 11, 2020
Study CompletionDec 4, 2020
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.0 years ago
Interventions
Jardiancedrug
Empagliflozin